Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis

Completed

Conditions studied: Amyotrophic Lateral Sclerosis

In brief

The role of hyperlipidemia and lipid lowering therapy (LLT) in Amyotrophic Lateral Sclerosis (ALS) pathophysiology and its impact on disease progression and survival is unclear. The investigators analyzed the correlation between lipid levels with disease progression and survival in ALS patients and the association of LLT with these outcomes.

Key facts

Study ID

NCT01592084

Run by

The Methodist Hospital Research Institute

People needed

267

Starts

2008-04-01

Expected to finish

2011-09-01

Last updated by the study team

2012-05-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A clinical diagnosis of laboratory-supported probable, probable, or definite familial, sporadic ALS, according to a modified El Escorial criteria (ref), by the study investigators
• Time from disease onset is less than three years
• 18 years of age
• Subjects with diagnosis of hyperlipidemia and/or taking lipid lowering medications will not be excluded from study.

You may not qualify if…

• Requirement for tracheotomy ventilation or non-invasive ventilation for > 23 hours per day
• Diagnosis of other neurodegenerative diseases (Parkinson disease, Alzheimer disease, etc)
• A clinically significant history of significant medical illness (advanced cancer, chronic inflammatory/infectious conditions, etc) within six months of baseline
• Use of progestins, anabolic steroids, and corticosteroids within 45 days of baseline visit. Therapy is allowed as medically indicated after baseline visit.

Where it is running

• the Methodist Neurological Institute — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.